These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 25618016)
41. High isoniazid resistance rates in rifampicin susceptible Mycobacterium tuberculosis pulmonary isolates from Pakistan. Fasih N; Rafiq Y; Jabeen K; Hasan R PLoS One; 2012; 7(11):e50551. PubMed ID: 23226311 [TBL] [Abstract][Full Text] [Related]
42. 2,2,2-trifluoro-1-(1,4,5,6-tetrahydropyridin-3-yl)ethanone derivative as efflux pump inhibitor in Mycobacterium tuberculosis. Halicki PCB; Vianna JS; Zanatta N; de Andrade VP; de Oliveira M; Mateus M; da Silva MV; Rodrigues V; Ramos DF; Almeida da Silva PE Bioorg Med Chem Lett; 2021 Jun; 42():128088. PubMed ID: 33964440 [TBL] [Abstract][Full Text] [Related]
43. Monocarbonyl curcuminoids as antituberculosis agents with their moderate in-vitro metabolic stability on human liver microsomes. Gagandeep ; Singh M; Kidawi S; Das US; Velpandian T; Singh R; Rawat DS J Biochem Mol Toxicol; 2021 Jun; 35(6):1-10. PubMed ID: 33751730 [TBL] [Abstract][Full Text] [Related]
44. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
45. Fidaxomicin has high Sun Q; Wang S; Liao X; Jiang G; Huang H; Li H; Wang G J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33593474 [TBL] [Abstract][Full Text] [Related]
46. Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis. Sahoo SK; Rani B; Gaikwad NB; Ahmad MN; Kaul G; Shukla M; Nanduri S; Dasgupta A; Chopra S; Yaddanapudi VM Eur J Med Chem; 2021 Oct; 222():113580. PubMed ID: 34116324 [TBL] [Abstract][Full Text] [Related]
47. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study. Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085 [TBL] [Abstract][Full Text] [Related]
48. Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance. Igarashi Y; Chikamatsu K; Aono A; Yi L; Yamada H; Takaki A; Mitarai S Diagn Microbiol Infect Dis; 2017 Dec; 89(4):276-281. PubMed ID: 28974394 [TBL] [Abstract][Full Text] [Related]
49. Synthesis and in vitro evaluation of novel substituted isatin-propylene-1H-1,2,3-triazole-4-methylene-moxifloxacin hybrids for their anti-mycobacterial activities. Yan X; Lv Z; Wen J; Zhao S; Xu Z Eur J Med Chem; 2018 Jan; 143():899-904. PubMed ID: 29227930 [TBL] [Abstract][Full Text] [Related]
50. Prevalence of Multi-Drug Resistant Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555 [TBL] [Abstract][Full Text] [Related]
51. Simple dihydrosphyngosine analogues with potent activity against MDR-Mycobacterium tuberculosis. Del Olmo E; Molina-Salinas GM; Escarcena R; Alves M; López-Pérez JL; Hernandez-Pando R; Said-Fernández S; Feliciano AS Bioorg Med Chem Lett; 2009 Oct; 19(19):5764-8. PubMed ID: 19703769 [TBL] [Abstract][Full Text] [Related]
52. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India. Mamatha HG; Shanthi V J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289 [TBL] [Abstract][Full Text] [Related]
54. Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing. He W; Tan Y; Liu C; Wang Y; He P; Song Z; Liu D; Zheng H; Ma A; Zhao B; Ou X; Xia H; Wang S; Zhao Y Microbiol Spectr; 2022 Feb; 10(1):e0154321. PubMed ID: 35171016 [TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis. Li P; Wang B; Li G; Fu L; Zhang D; Lin Z; Huang H; Lu Y Eur J Med Chem; 2020 Nov; 206():112538. PubMed ID: 32927218 [TBL] [Abstract][Full Text] [Related]
56. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134 [TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612 [TBL] [Abstract][Full Text] [Related]
58. Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis. Hoffman AE; DeStefano M; Shoen C; Gopinath K; Warner DF; Cynamon M; Doyle RP Eur J Med Chem; 2013; 70():589-93. PubMed ID: 24211634 [TBL] [Abstract][Full Text] [Related]